NSABP Foundation

January 9, 2019

FDA OKs Phase 2 Trial of AE37-Keytruda Combo in Metastatic Triple-negative Breast Cancer

News

Generex Biotechnology is planning a Phase 2 trial to test a combination of its AE37 peptide vaccine and Keytruda (pembrolizumab) in patients with advanced triple-negative breast cancer, after the U.S. Food and Drug Administration ... Read more

December 3, 2018

Planned Phase 2 Trial to Test Vaccine in Triple-negative Breast Cancer Patients, Generex Says

News

Generex Biotechnology has entered into an agreement with the NSABP Foundation to manage a possible Phase 2 clinical trial testing an anti-cancer vaccine in patients with metastatic triple negative breast cancer. ... Read more